Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.
暂无分享,去创建一个
M Buyse | M. Buyse | E. Saad | E D Saad | Marc Buyse
[1] M. Buyse,et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[3] D. Sargent,et al. Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.
[4] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[5] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[6] Tomasz Burzykowski,et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. , 2009, The Lancet. Oncology.
[7] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[8] R. Temple,et al. Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.
[9] G. Giaccone,et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[11] S. Devesa,et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. , 2004, Journal of the National Cancer Institute.
[12] Robert Pirker,et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.
[13] T. Chevalier,et al. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[15] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[17] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[18] D. Sargent,et al. Survival is not a good outcome for randomized trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[20] E. Eisenhauer,et al. Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Barni,et al. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Taguri,et al. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[24] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[25] J. Tabernero,et al. Progression-free survival: helpful biomarker or clinically meaningless end point? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Buyse,et al. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Thigpen. Issues in Using Progression-Free Survival When Evaluating Oncology Products , 2010 .
[29] M. Garnick. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study. , 2013, Journal of Clinical Oncology.
[30] K. Behrns. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .
[31] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Keegan,et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. , 2010, Journal of the National Cancer Institute.
[33] M. Morris. Failure of ELM-PC 5: an ineffective drug or an unfit end point? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Sargent,et al. Assessing the measure of a new drug: is survival the only thing that matters? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Buyse,et al. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[38] R. Motzer,et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[40] Shigeyuki Matsui. Design and Analysis of Clinical Trials for Predictive Medicine , 2015 .
[41] J. T. Thigpen. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011 .
[42] C. Tournigand,et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Michael Scholz,et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[45] Norbert Hollaender,et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.
[46] C. Garnett,et al. U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis , 2012, Clinical Cancer Research.
[47] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[48] Michael Scholz,et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). , 2013 .
[49] Greg Yothers,et al. Toward progression-free survival as a primary end point in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[51] Kristine R Broglio,et al. Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.
[52] M. Buyse,et al. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.